BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25307987)

  • 21. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
    Partelli S; Gaujoux S; Boninsegna L; Cherif R; Crippa S; Couvelard A; Scarpa A; Ruszniewski P; Sauvanet A; Falconi M
    JAMA Surg; 2013 Oct; 148(10):932-9. PubMed ID: 23986355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
    Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
    World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroendocrine tumors of the pancreas: current concepts and controversies.
    Reid MD; Balci S; Saka B; Adsay NV
    Endocr Pathol; 2014 Mar; 25(1):65-79. PubMed ID: 24430597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.
    Hermann G; Konukiewitz B; Schmitt A; Perren A; Klöppel G
    Virchows Arch; 2011 Aug; 459(2):147-54. PubMed ID: 21739268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.
    Xue Y; Reid MD; Pehlivanoglu B; Obeng RC; Jiang H; Memis B; Lui SK; Sarmiento J; Kooby D; Maithel SK; El-Rayes B; Basturk O; Adsay V
    Endocr Pathol; 2020 Sep; 31(3):239-253. PubMed ID: 32488621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cystic pancreatic neuroendocrine tumors: a clinicopathologic study.
    Singhi AD; Chu LC; Tatsas AD; Shi C; Ellison TA; Fishman EK; Kawamoto S; Schulick RD; Wolfgang CL; Hruban RH; Edil BH
    Am J Surg Pathol; 2012 Nov; 36(11):1666-73. PubMed ID: 23073325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Infiltrative Macroscopic Growth Pattern and Infiltrative Microscopic Tumor Border Status Is a Novel Surrogate Marker of Poor Prognosis in Patients With Pancreatic Neuroendocrine Tumor.
    Ahn B; Kim JY; Hong SM
    Arch Pathol Lab Med; 2023 Jan; 147(1):100-116. PubMed ID: 35533360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
    Farrell JM; Pang JC; Kim GE; Tabatabai ZL
    Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade.
    Takumi K; Fukukura Y; Higashi M; Ideue J; Umanodan T; Hakamada H; Kanetsuki I; Yoshiura T
    Eur J Radiol; 2015 Aug; 84(8):1436-1443. PubMed ID: 26022520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors.
    Yadav R; Kakkar A; Sharma A; Malik PS; Sharma MC
    Scand J Gastroenterol; 2016 Aug; 51(8):994-9. PubMed ID: 27162024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors.
    Zhou B; Xiang J; Jin M; Zheng X; Li G; Yan S
    BMC Cancer; 2021 Mar; 21(1):334. PubMed ID: 33789624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours.
    Kajtazi Y; Kaemmerer D; Sänger J; Schulz S; Lupp A
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2481-2493. PubMed ID: 31451931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2.
    Panarelli NC; Yantiss RK; Yeh MM; Liu Y; Chen YT
    Am J Clin Pathol; 2012 Aug; 138(2):211-22. PubMed ID: 22904132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.
    Singhi AD; Klimstra DS
    Histopathology; 2018 Jan; 72(1):168-177. PubMed ID: 29239037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors.
    Galván JA; Astudillo A; Vallina A; Fonseca PJ; Gómez-Izquierdo L; García-Carbonero R; González MV
    Am J Clin Pathol; 2013 Jul; 140(1):61-72. PubMed ID: 23765535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor.
    Lee YS; Kim H; Kim HW; Lee JC; Paik KH; Kang J; Kim J; Yoon YS; Han HS; Sohn I; Cho J; Hwang JH
    Medicine (Baltimore); 2015 Dec; 94(50):e2224. PubMed ID: 26683934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors.
    Liu TC; Hamilton N; Hawkins W; Gao F; Cao D
    Am J Surg Pathol; 2013 Jun; 37(6):853-9. PubMed ID: 23598967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
    Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reappraisal of Malignant Risk Assessment for Small (≤20 mm) Non-functioning Pancreatic Neuroendocrine Tumors.
    Nanno Y; Toyama H; Matsumoto I; Uemura J; Asari S; Goto T; Lee D; Murakami T; Komatsu S; Yanagimoto H; Kido M; Ajiki T; Okano K; Takeyama Y; Fukumoto T
    Ann Surg Oncol; 2023 Jun; 30(6):3493-3500. PubMed ID: 36795254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological Features of Intraductal Pancreatic Neuroendocrine Tumors.
    Chang XY; Jia CW; Meng YX; Chen J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):568-573. PubMed ID: 27825416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.